Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775946 | 0.85 | HTR6 (0.69) | HTR6HSD11B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1775865 | 0.84 | HTR6 (0.67) | HTR6HSD11B1 | |
| SCHEMBL27710758 | 0.76 | HSD11B1 (0.50) | HSD11B1GAARBP4MEN1KMT2A | |
| SCHEMBL1774570 | 0.75 | HTR6 (0.62) | HTR6GBA1HTR1A | |
| SCHEMBL1776334 | 0.75 | RECQL (0.49) | HTR6GAAMEN1KMT2A | |
| SCHEMBL3095680 | 0.73 | HSD11B1 (0.76) | HSD11B1GAARBP4TRPA1 | |
| SCHEMBL1774568 | 0.72 | HTR6 (0.58) | HTR6HTR1A | |
| SCHEMBL18437355 | 0.71 | HTR6 (0.75) | HTR6HTR1A | |
| SCHEMBL1775734 | 0.70 | HTR6 (0.46) | HTR6MEN1KMT2AHTR1A | |
| SCHEMBL3320963 | 0.69 | HSD11B1 (0.57) | HSD11B1GAARBP4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HTR6 2109/4885HSD11B1 497/4885GAA 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.